Syensqo

Syensqo reported adjusted EBITDA for Q2 2026 of €311m (consensus €292m) and net revenue of €1,554m (consensus €1,485m), beating market expectations. Management raised its full‑year targets: EBITDA from “around €1.1bn” to “at least €1.1bn” and volume growth from “low single‑digit” to “low to mid single‑digit.” The results and the guidance raise removed lingering uncertainty and pushed the share price sharply higher; it traded at €77.60, well above the 52‑week low but below the high. » Plus sur de.investing.com

Syensqo has announced a strategic review of its Performance & Care segment, which includes Novecare and Technology Solutions. The aim is to reposition the company as a pure-play provider of specialty materials and advanced technologies to maximize long-term value for shareholders. The company plans to focus more on markets such as aerospace, defense, electronics, healthcare, energy and advanced mobility. » Plus sur de.investing.com

Syensqo reported net revenue of €1.52bn in Q3 2025 (−1% YoY) with an EBITDA margin of over 23% and EBITDA of €326m. The company generated free cash flow of €250m, has executed 60% of the €300m buyback program and targets cost savings of more than €200m by 2026. The share rose 2.91% to €70.04 after the results. Syensqo expects adjusted EBITDA of around €1.25bn for 2025 and lower results in Q4 ahead of an anticipated market recovery in 2026. » Plus sur de.investing.com